(Q37609270)

21 August 2017

title

Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia (English)

1 reference

21 August 2017

0 references

1 reference

Rena Kurs

2

0 references

author name string

Michael Ritsner

series ordinal

1

1 reference

21 August 2017

publication date

1 August 2002

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

21 August 2017

published in

1 reference

21 August 2017

volume

2

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

347-356

1 reference

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Measures of quality of life among persons with severe and persistent mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Measuring quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Refining quality of life: validating a multidimensional factor measure in the severe mentally ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Subject and observer-rated quality of life in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: The South Verona Outcome Project 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Detecting improvement in quality of life and symptomatology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

The well-being of chronic mental patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Convergent validation of quality of life assessments for persons with severe mental illnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Quality of life in treated and never-treated schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2.4.347

21 January 2018

Identifiers

DOI

10.1586/14737167.2.4.347

1 reference

21 August 2017

1 reference